ARS Pharmaceuticals (SPRY) Stock: Buy, Sell, or Hold?
SPRY - ARS Pharmaceuticals, Inc. Common Stock
$4.07
-0.05 (-1.21%)
▼
5d:
-0.25%
30d:
-30.07%
90d:
-51.14%
HOLD
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 09, 2026
Get Alerted When SPRY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: SPRY shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: SPRY shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: SPRY is currently trading at $4.07, which is considered oversold relative to its 30-day fair value range of $4.15 to $5.63.
Technical Outlook: Technically, SPRY is in a strong downtrend. The price is currently testing key support at $3.98. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SPRY scores 84/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $22.50 (+452.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SPRY is in a strong downtrend. The price is currently testing key support at $3.98. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SPRY scores 84/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $22.50 (+452.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.15 -
$5.63
Company Quality Score
66/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
94.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (84/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 452.8% below Wall St target ($22.50)
- CAUTION: Bottoming setup, but lagging the sector by 42% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$4.15 -
$5.63
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.99
Resistance Level
$4.57
Current Trend
Strong Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.54
Wall Street Target
$22.50
(+452.8%)
Revenue Growth (YoY)
114.2%
Profit Margin
-184.2%
Share & Embed Analysis
Last updated: October 03, 2026 1:11 PM ET
Data refreshes hourly during market hours. Next update: 2:11 PM
Data refreshes hourly during market hours. Next update: 2:11 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SPRY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$92 | 46 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 76 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$47 | 46 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 65 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 42 HOLD |
